Novo Nordisk Buys Another Obesity Drugmaker as Wegovy Fever Continues to Rise

Novo Nordisk has acquired Embark Biotech, as the larger Danish drugmaker looks to expand its blockbuster obesity drug portfolio in the wake of surging economic demand and rising market shortages of both metabolic and diabetes therapies.
Source: Drug Industry Daily